LEO Pharma appoints Paul Navarre new member of its Board of Directors
Paul Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the position as CEO of Ferring US Holding subsequent to ten years at Allergan, among other as President of International Operations (global except US) and President of EAME (Europe, Middle East and Africa). Prior to that, he spent 15 years at Procter & Gamble managing multiple countries and global brands in pharmaceuticals and Health and beauty care.
Paul Navarre has a solid track record of delivering sustainable top line growth and building high performance organizations in the specialty pharmaceutical business through scientific innovation and customer centric approaches.
“With his impressive career, Paul brings extensive strategic and commercial experience from the global biotech and dermatology market, that will be of great value to LEO Pharma in its ambitions to create future growth and become a top five company within medical dermatology. I am excited to be working together with Paul going forward”, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.
“It’s a privilege to join the Board of Directors at LEO Pharma at this time in the company’s history. With its ongoing transformation, many steps have already been taken to position the company for future growth and I look much forward to being part of continuing this development”, said Paul Navarre.
Paul Navarre was elected one of the Top 100 Most Inspiring People by PharmaVoice in 2019. In 2021 he completed the Insead Corporate Governance Course.
Contacts
Contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse
Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1
LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 202515.9.2025 15:00:00 CEST | Pressemeddelelse
For the second year in a row, LEO Pharma delivers its largest and most ambitious scientific programme ever at the 2025 European Academy of Dermatology and Venereology (EADV), setting a new standard by presenting an unprecedented volume of scientific content for the company, with 5 late-breaking presentations and 24 regular abstracts.1-29 LEO Pharma’s scientific programme at EADV 2025 spans multiple dermatological indications, mirroring the company’s strong commitment to addressing both the most prevalent chronic skin diseases and hard-to-treat conditions.1-29 Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio.1-29
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth18.8.2025 12:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2025 - In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted EBITDA margin in 2025 towards the upper-end of previously communicated expectations. In July, the FDA approval of Anzupgo® and partnership with Boehringer Ingelheim for SPEVIGO®, marked major strategic milestones demonstrating LEO Pharma’s commitment to advancing innovation in dermatology. Highlights LEO Pharma’s revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 51% (CER). Sales
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:30:00 CEST | Pressemeddelelse
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom